Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ixaka","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$55.9 million","upfrontCash":"Undisclosed","newsHeadline":"Ixaka (Formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Ixaka","sponsor":"SomaLogic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ixaka and SomaLogic Enter Research Collaboration to Develop Bispecific Agents for Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Ixaka","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ixaka Expands IP Portfolio to Enable Use of Targeted Nanoparticle in vivo Gene Delivery Technology With Any Cargo in Any Therapeutic Area","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Ixaka","sponsor":"Alaya.bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alaya.bio Acquires Key Assets from Ixaka France, Accelerating the Progress of its Novel In Vivo CAR-T Immunotherapy Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Ixaka

    Menu

    Ixaka

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ixaka

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alaya.bio Acquires Key Assets from Ixaka France, Accelerating the Progress of its Novel In Vivo CAR-T Immunotherapy Platform

              Details:

              Through the acquisition, Alaya.bio intends to leverage its combined assets to significantly simplify the way CAR-T cell therapies are being developed, manufactured and administered.

              Lead Product(s): CAR T-cell Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Alaya.bio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition October 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ixaka

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ixaka Expands IP Portfolio to Enable Use of Targeted Nanoparticle in vivo Gene Delivery Technology With Any Cargo in Any Therapeutic Area

              Details:

              TNP – composed of proprietary polymer capsule ‘OM-PBAE’ polymers (oligopeptide end-modified poly β-amino-ester polymers) directed to specific cells through targeting agents attached capsule (an aptamer-based targeting moiety) and celtic (Lentivirus Based CAR T-cell Therapy).

              Lead Product(s): Lentivirus Based CAR T-cell Therapy

              Therapeutic Area: Oncology Product Name: Celtic

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ixaka

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ixaka and SomaLogic Enter Research Collaboration to Develop Bispecific Agents for Oncology

              Details:

              The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer® reagents previously identified and screened by SomaLogic as potential candidates for combination with Ixaka’s anti-CD3 aptamers.

              Lead Product(s): AntigenxCD3 Bispecific Aptamers

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Recipient: SomaLogic

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ixaka

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ixaka (Formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company

              Details:

              The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies and targeted nanoparticle therapeutics. REX-001, Ixaka’s lead MCT product, is an autologous cell-based product in clinical development for the treatment of CLTI.

              Lead Product(s): Rexmyelocel-T

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: REX-001

              Highest Development Status: Phase III Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $55.9 million Upfront Cash: Undisclosed

              Deal Type: Financing January 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY